Prognostic Significance Of Beta-Catenin Expression In Patients With Non-Small Cell Lung Cancer: A Meta- Analysis

Background: beta-catenin is a key component of the canonical Wnt pathway, which plays pivotal roles in malignant transformation and cancer progression. Several studies have reported the clinical significance of the expression level of beta-catenin in different subcellular locations. This meta-analysis aimed to assess the prognostic value of a-catenin expression patterns in patients with non-small cell lung cancer (NSCLC).Methods: PubMed and Embase databases were searched to identify all articles referring to the association between a-catenin expression level and outcomes of patients of NSCLC up to November 2016. We included eligible studies to summarize the extracted data in terms of pooled hazard ratios (HRs) and their 95% confidence intervals (95% CIs).Results: A total of 24 studies published between 2000 and 2016 were eligible for this meta-analysis. The total number of patients with NSCLC included was 2,807. Pooled HRs and 95% CIs suggested that positive beta-catenin expression in membrane was associated with higher survival rates (HR: 0.53; 95% CI: 0.32-0.87), whereas a-catenin expression in cytoplasm and nucleus had unfavorable impacts on survival rates with HR of 1.63 (95% CI: 1.34-1.99) and HR of 3.15 (95% CI: 1.97-5.05), respectively. But, there was no significant association between a-catenin expression in abnormal pattern with prognosis (HR: 1.38; 95% CI: 0.61-3.15). Publication bias was absent in all of the four outcomes. Sensitivity analysis revealed that the results of this meta-analysis were robust.Conclusions: Reduced membranous a-catenin, positive expression of cytoplasmic or nuclear beta-catenin is all correlated with poor prognosis, although we did not identify a significant association between abnormal beta-catenin expression and clinical outcome of NSCLC patients. The meta-analysis suggested that membranous, cytoplasmic and nuclear a-catenin all could serve as an important prognosticator for patients with NSCLC.